CTRI/2019/10/021832已完成未知
A randomized double blind placebo controlled Safety and efficacy study of Lenoid, a topical treatment for symptoms relief in patients with haemorrhoids
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Giellepi Spa
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects willing to give written informed consent.
- •2.Male or female subjects, more than 18 years of age with a diagnosis of haemorrhoids (first or second degree). â?¨
- •3.Except haemorrhoids (first or second degree), the subjects are judged to be in good general health, based on medical history, physical examination. â?¨
- •4.If female of childbearing age, they should be willing to use an acceptable form of birth control measure. They should be stable since last 3 months prior to baseline â?¨and throughout the study. â?¨
- •5.Subjects accepting to be on controlled and balanced diet (with exclusion of â?¨some foods including hot chili, pepper, chocolate, alcoholic drinks, fried foods). Tea and coffee will be restricted to not more of 2 cups per day.
- •6.Subjects who were on phlebotonic drugs but who are not on the medications since 2 months before the recruitment can be included in the study.
排除标准
- •1.Pregnant and lactating women and women in post-partum period of up to 6 weeks. â?¨
- •2.Subjects with a history of permanent anal prolapse and/or anal fissures and/or infective anal pathology. â?¨
- •3.Subjects with previous history of surgery for anorectal disease (within 5 years) or any other procedures (including but not limited to injection sclerotherapy, rubber band ligation, photocoagulation, cryotherapy etc) within 2 years of enrolment into the trial. â?¨
- •4.Subjects who, in the opinion of the investigator, are mentally incapacitated such that informed consent cannot be obtained. â?¨
- •5.Subjects with clinically significant co-morbid condition that in the opinion of the investigator could affect the efficacy and safety outcome of the study. â?¨
- •6.Patients under treatment with other topical therapy for haemorrhoidal syndrome.
- •7.Patients under treatment with plebotonic drugs or phlebotonic dietary supplements (i.e. diosmin etc.).
- •8.Subjects participating in any other clinical trial currently or if he/she has completed the trial participation less than 3 months from screening for the current study.
- •9.Presence of disease states that could affect safety and efficacy â?¨evaluation, such as hepatic (e.g., cirrhosis with Child-Pugh Class B or C or MELD score > 9), renal (e.g., requiring dialysis), gastrointestinal (e.g., acute or chronic diverticulitis, irritable bowel syndrome with epigastric pain as a predominant symptom or active inflammatory bowel disease), hematologic, neurologic or brain disorders (e.g., strokes, and brain injury), psychiatric (e.g., bipolar disorder, severe active depression, severe active anxiety), or any other significant condition which, in the opinion of the Investigator, could confound or interfere with evaluation of efficacy, safety, or tolerability of the investigational drug, or prevent compliance with the study protocol.â?¨
- •10.Subjects unwilling to sign the inform consent document.
- •11.Any condition that in the opinion of the investigator does not justify the subjectsâ?¨inclusion for the study.
- •12.Known hypersensitivity to, or intolerance of, investigational product or any excipient.
- •13.During the course of the study no other medications should be consumed. Only rescue medications to be used with the recommendatuons from the Pricipal Investigtor and this should be recorded in the CRF.
研究者
相似试验
已完成
Unknown
A clinical study to check the safety and effectiveness of plant-based Biotin and plant-based Biotin with Silica in Healthy Human who had complaints of hair fall, thin dry and brittle hair and dry skiCTRI/2023/07/055359ORGENETICS INC105
尚未招募
2 期
A randomized double blind placebo controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemiaatherosclerosis10003216familial hypercholesterolemiaNL-OMON32563ovartis20
进行中（未招募）
不适用
A randomized, double blinded placebo controlled study to investigate antimicrobial efficacy and safety following topical application of DPK-060. Final protocol dated 2007-12-19. CRO protocol no. Q-27318. Final protocol incorporating amendment 1 dated 2008-08-28. Amendment 2 dated 2008-10-01.Atopic dermatitisEUCTR2007-007103-32-SEDermaGen AB
已完成
4 期
Clinical study to study the efficacy and safety of KSM- 66 Ashwagandha (Withania Somnifera) cardiac endurance and Oxidative Stress in Athletes / Sports personsCTRI/2016/04/006791Shri Karthikeya Pharma50
已完成
4 期
Study to evaluate the efficacy and safety of KSM- 66 Ashwagandha on sexual wellness of healthy male subjectsCTRI/2016/05/006906Shri Karthikeya Pharma50